Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 10, 2017

Primary Completion Date

October 29, 2018

Study Completion Date

October 29, 2018

Conditions
Plaque PsoriasisSkin Diseases
Interventions
DRUG

JTE-051

Active drug tablets containing JTE-051

DRUG

Placebo

Placebo tablets identical in appearance to the active drug tablets

Trial Locations (16)

11375

Forest Hills Dermatology Group, Forest Hills

29407

Clinical Research Center of the Carolinas, Charleston

29621

Radiant Research, Inc., Anderson

30022

Atlanta Dermatology Vein and Research Center LLC, Alpharetta

30328

Advanced Medical Research, PC, Sandy Springs

33612

University of South Florida - Hospital, Tampa

47714

Clinical Research Advantage, Inc., Evansville

75230

Dermatology Treatment and Research Center, Dallas

83651

Advanced Clinical Research - Dermatology Center of Canyon County, Nampa

92708

First OC Dermatology, Fountain Valley

94538

Center For Dermatology Clinical Research, Inc., Fremont

66215-2309

Kansas City Dermatology P.A., Overland Park

A1A 4Y3

Karma Clinical Trials, St. John's

N5X 2P1

Mediprobe Research Inc., London

L3P 1X2

Lynderm Research Inc., Markham

H3H 1V4

David Gratton's Private Practice, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Akros Pharma Inc.

INDUSTRY